In the multivariate logistic regression analysis, age ≥ 60 years, tumor stages III-IV, prechemotherapy PDW ≤ 12.6%, prechemotherapy albumin concentration ≤ 38.8 g/L, prechemotherapy LDH concentration ≥ 198 U/L, prechemotherapy D-dimer concentration ≥ 1.72 μg/mL, prechemotherapy blood hemoglobin concentration ≤ 100 g/dL or use of erythropoiesis-stimulating agents, and cancer types were independently correlated with VTE in solid tumor patients (Table 2). The gene discussed is ALB; the disease is neoplasm.